Clinical and Biochemical Evaluation of LY2963016: A Comprehensive Study of Insulin Glargine Biosimilarity to Lantus®
DOI:
https://doi.org/10.61173/n979q751Keywords:
LY2963016 insulin glargine, biosimilar in-sulin, insulin glargine, bioequivalence, immunogenicityAbstract
The first biosimilar insulin LY2963016 insulin glargine (Abasaglar) received regulatory approval in Europe, marking a significant step as biosimilar insulin products enter the market. Given that insulin products are complex biological agents produced through intricate biotechnological processes, they are not identical to their reference products. This article reviews a series of experiments to compare the bioequivalence of LY2963016 insulin glargine (LY IGlar) and reference insulin glargine (Lantus, IGlar) in patients with type 1 or type 2 diabetes, assessing structure, pharmacokinetics, efficacy and safety, and duration of action. Additionally, their immunogenicity profiles and their potential impact on clinical outcomes were were examined, demonstrating comparable outcomes between LY IGlar and IGlar in terms of bioequivalence and immunogenicity.
References
[1] Dos Reis C, Teixo R, Mendes F, Cruz RS. Biosimilar medicines - Review. Int J Risk Saf Med. 2016, 28(1):45-60.
[2] European Medicines Agency. (2014). Abasaglar insulin glargine: EPAR summary for the public. Retrieved January 27, 2017, from http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Summary_for_the_public/human/002835/ WC500175384.pdf Last accessed 27 January 2017.
[3] Sanofi. (n.d.). Lantus® (insulin glargine [rDNA origin] injection) solution for subcutaneous injection: Prescribing information. Retrieved October 23, 2015, from https://products. sanofi.us/lantus/lantus.html.
[4] Eli Lilly and Company. (2014). European Commission grants Lilly and Boehringer Ingelheim’s insulin glargine product marketing authorisation in Europe. Retrieved October 23, 2015, from http://investor.lilly.com/releasedetail. cfm?ReleaseID=870088.
[5] Altman JJ, Chevalier N, Delemer B, et al. Développement des biosimilaires de l’insuline : exemple de l’insuline glargine LY2963016 [LY2963016 insulin glargine: The first biosimilar insulin approved in the European Union]. Presse Med. 2018,47(10):854-866. French.
[6] Davies M, Dahl D, Heise T, et al. Introduction of biosimilar insulins in Europe. Diabet Med. 2017 Oct;34(10):1340-1353.
[7] European Medicines Agency. (2014). Public assessment report: EMA/CHMP/340840/2014. Retrieved January 11, 2017, from http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Public_assessment_report/human/002835/ WC500175383.pdf
[8] H. Linnebjerg, E.C. Lam, M.E. Seger,et al.Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and European Union- and U.S.-approved versions of Lantus insulin glargine in healthy subjects:three randomized euglycemic clamp studies Diabetes Care, 2015,38 (12) .
[9] Laekeman, G. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. 2013. https:// doi.org/10.123456789/401620.
[10] T.C. Blevins, D. Dahl, J. Rosenstock, L.L. Ilag, W. J. Huster, J.S. Zielonka, et al.Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study Diabetes Obes Metab, 2015,17 (8).
[11] Rosenstock J, Hollander P, Bhargava A etal. Similar efficacy and safety with LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulinnaïve or previously treated with insulin glargine: a randomized, double blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab 2015, 17: 734–741.
[12] Ilag LL, Deeg MA, Costigan T, et al. Evaluation of Dean&Francis Xinran Wang immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus. Diabetes Obes Metab. 2016,18(2):159-68.
[13] Blevins TC, Dahl D, Rosenstock J etal. Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomised controlled trial (The ELEMENT 1 Study). Diabetes Obes Metab. 2015, 17: 726–733.
[14] Van de Vooren K, Curto A, Garattini L,et al . Biosimilar versus generic drugs: same but different? Appl Health Econ Health Policy. 2015, 13: 125–127.
[15] 57Farfan-Portet MI, Gerkens S, Lepage-Nefkens I, Vinck I, et al . Are biosimilars the next tool to guarantee costcontainment for pharmaceutical expenditures? Eur J Health Econ.2014, 15: 223–228.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
